Fig. 6
4A7 significantly enhances paclitaxel-mediated antitumor activity in TNBC tumor xenograft models. HCC1806-luc cells (5 × 105) were orthotopically inoculated into the mammary fat pads of nude mice to establish tumor xenografts. When tumor volume reached ~ 80mm3, the tumor-bearing mice received intraperitoneal injections of PBS, 4A7 (20 mg/kg), paclitaxel (6 mg/kg), or both 4A7 and paclitaxel (Pac + 4A7) (n = 5). After 6 treatments, mice were sacrificed. A, Tumor growth curves were plotted using average tumor volumes within each group at the indicated time points. A two-tailed student’s t-test was used for statistical analysis. Bars, SEM. *, P < 0.01. B, The mammary tumors were dissected and imaged as indicated (Left). The tumors were also measured for weight (Right). Bars, SD. *, p < 0.05, ***, p < 0.005. C and D, At end of the experiments, before mice were sacrificed, bioluminescent imaging of the mammary tumors was obtained with the IVIS spectrum (C). The luciferase signal intensity of the mammary tumors from the mice of each treatment group was plotted. Bars, SD. *, p < 0.05, **, p < 0.01. E, Formalin-fixed paraffin-embedded sections of tumors were analyzed with IHC staining for p-HER3 (Y1289), p-EGFR (Y1068), Ki67, or cleaved Caspase-3 (C-caspase-3). Scale bar, 70 μm. Quantification of IHC staining with ImageJ and ImageJ plugin IHC profiler was shown underneath. A two-way ANOVA tests were used for statistical analysis. Bars, SD. *, p < 0.05, ****, p < 0.001